These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38244434)

  • 1. Getting to know ovarian cancer: Focusing on the effect of LncRNAs in this cancer and the effective signaling pathways.
    Alzahrani AA; Almajidi YQ; Jasim SA; Hjazi A; Olegovich BD; Alkhafaji AT; Abdulridui HA; Ahmed BA; Alawadi A; Alsalamy A
    Pathol Res Pract; 2024 Feb; 254():155084. PubMed ID: 38244434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
    Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
    Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.
    Braga EA; Fridman MV; Moscovtsev AA; Filippova EA; Dmitriev AA; Kushlinskii NE
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
    Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
    Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA CDKN2A-AS1 facilitates tumorigenesis and progression of epithelial ovarian cancer via modulating the SOSTDC1-mediated BMP-SMAD signaling pathway.
    Zhao Q; Dong D; Chu H; Man L; Huang X; Yin L; Zhao D; Mu L; Gao C; Che J; Liu Q
    Cell Cycle; 2021 Jun; 20(12):1147-1162. PubMed ID: 34110955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical important of LncRNA-HOTAIR gene variations and ovarian cancer susceptibility.
    Saeedi N; Ghorbian S
    Mol Biol Rep; 2020 Oct; 47(10):7421-7427. PubMed ID: 32901358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by targeting miR-182-5p/FOXF2 signaling pathway.
    Wang A; Jin C; Li H; Qin Q; Li L
    Int J Biol Macromol; 2018 Dec; 120(Pt B):1705-1713. PubMed ID: 30268751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer.
    Worku T; Bhattarai D; Ayers D; Wang K; Wang C; Rehman ZU; Talpur HS; Yang L
    Cell Physiol Biochem; 2017; 44(3):948-966. PubMed ID: 29179183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of long non‑coding RNA CCEPR is associated with poor prognosis and contributes to the progression of ovarian cancer through regulating the Wnt/β‑catenin signaling pathway.
    Chen Z; Zhu Y; Fan X; Liu Y; Feng Q
    Mol Med Rep; 2020 Apr; 21(4):1950-1958. PubMed ID: 32319633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.
    Sun T; Yang P; Gao Y
    Exp Physiol; 2020 Jan; 105(1):75-87. PubMed ID: 31645082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway.
    Lin X; Feng D; Li P; Lv Y
    Cancer Med; 2020 Nov; 9(21):8122-8132. PubMed ID: 32918541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNAs and MiRNAs: New Targets for Resveratrol in Ovarian Cancer Research.
    Chaichian S; Bidgoli SA; Nikfar B; Moazzami B
    Curr Med Chem; 2023; 30(28):3238-3248. PubMed ID: 36372916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
    Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
    Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
    Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of EMT-Related lncRNAs in Ovarian Cancer.
    Lampropoulou DI; Papadimitriou M; Papadimitriou C; Filippou D; Kourlaba G; Aravantinos G; Gazouli M
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
    Li H; Zhou Y; Cheng H; Tian J; Yang S
    Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes transferring long non-coding RNA FAL1 to regulate ovarian cancer metastasis through the PTEN/AKT signaling pathway.
    Zhang Q; Len TY; Zhang SX; Zhao QH; Yang LH
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):43-54. PubMed ID: 31957817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes.
    Tripathi MK; Doxtater K; Keramatnia F; Zacheaus C; Yallapu MM; Jaggi M; Chauhan SC
    Drug Discov Today; 2018 Sep; 23(9):1635-1643. PubMed ID: 29698834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.